Mechanisms of resistance to CAR T cell therapies. (October 2020)

• Record Type: Journal Article
• Authors: Singh, Nathan; Orlando, Elena; Xu, Jun; Xu, Jie; Binder, Zev; Collins, McKensie A.; O'Rourke, Donald M.; Melenhorst, J. Joseph
• Is Part Of: Seminars in cancer biology. Volume 65(2020)
• Page Start: 91
• Page End: 98
• Publication Date: 2020-10
• Subjects: Chimeric antigen receptor -- Resistance; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2019.12.002
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.